v3.25.2
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Total revenue $ 2,645.5 $ 2,464.9 $ 5,076.5 $ 4,755.4
Cost and expenses:        
Cost of sales, excluding amortization and impairment of acquired intangible assets 605.0 546.0 1,234.3 1,088.2
Research and development 399.0 505.4 833.1 950.8
Acquired in-process research and development, upfront and milestone expense 46.6 8.5 247.3 16.0
Selling, general and administrative 583.8 553.8 1,156.3 1,135.3
Amortization and impairment of acquired intangible assets 130.9 86.9 242.7 165.2
Collaboration profit sharing/(loss reimbursement) 75.0 62.4 133.1 128.0
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) 13.2 0.0 22.8 0.0
Restructuring charges (0.7) 6.6 34.6 18.1
Gain on sale of priority review voucher, net 0.0 (88.6) 0.0 (88.6)
Other (income) expense, net 48.7 85.2 117.1 178.9
Total cost and expense 1,901.5 1,766.2 4,021.3 3,591.9
Income before income tax (benefit) expense 744.0 698.7 1,055.2 1,163.5
Income tax (benefit) expense 109.2 115.1 179.9 186.5
Net income attributable to Biogen Inc. $ 634.8 $ 583.6 $ 875.3 $ 977.0
Net income per share:        
Basic earnings per share attributable to Biogen Inc. (in USD per share) $ 4.33 $ 4.01 $ 5.98 $ 6.72
Diluted earnings per share attributable to Biogen Inc. (in USD per share) $ 4.33 $ 4.00 $ 5.97 $ 6.70
Weighted-average shares used in calculating:        
Basic earnings per share attributable to Biogen Inc. (in USD per share) 146,500 145,600 146,300 145,400
Diluted earnings per share attributable to Biogen Inc. (in USD per share) 146,700 145,900 146,700 145,900
Product revenue, net        
Total revenue $ 1,878.7 $ 1,899.6 $ 3,605.2 $ 3,611.5
Revenue from anti-CD20 therapeutic programs        
Total revenue 467.3 444.5 845.5 838.5
Alzheimer's collaboration revenue        
Total revenue 54.9 11.8 87.9 14.6
Contract manufacturing, royalty and other revenue        
Total revenue $ 244.6 $ 109.0 $ 537.9 $ 290.8